What baseline laboratory tests are recommended before initiating testosterone replacement therapy in a male patient?

Baseline Laboratory Tests for Testosterone Therapy

Before initiating testosterone replacement therapy in males, you must obtain: baseline testosterone level (measured on two separate mornings), hematocrit, PSA with digital rectal examination (for men ≥40 years old with PSA >0.6 ng/ml), and document symptoms of hypogonadism. 1

Essential Pre-Treatment Labs

Testosterone Measurement

• Two separate fasting morning total testosterone levels are required to confirm hypogonadism 1, 2
• Both measurements should be below 300 ng/dL (10.4 nmol/liter) to establish diagnosis
• Timing matters: draw between 7-11 AM when testosterone peaks naturally
• If sex hormone-binding globulin (SHBG) is altered (obesity, aging, diabetes), consider adding free testosterone measurement 3

Hematocrit/Hemoglobin

• Baseline hematocrit is mandatory 1, 4
• Critical threshold: Hematocrit >50% is a relative contraindication to testosterone therapy 1
• Men with hematocrit >50% require further clinical evaluation before considering therapy, as they may develop dangerous polycythemia (hematocrit >54%) on treatment 1
• This is a safety issue—testosterone dose-dependently increases hemoglobin, especially in older men 1

Prostate Screening (Age-Dependent)

For men ≥40 years old with baseline PSA >0.6 ng/ml: 1

• Baseline PSA level
• Digital rectal examination (DRE)
• If PSA >4.0 ng/ml or abnormal DRE: obtain prostate biopsy before initiating therapy 5

For men 55-69 years or men 40-69 years at increased prostate cancer risk: 2

• PSA and DRE should be performed if patient chooses prostate monitoring
• Combined PSA and DRE improves cancer detection compared to either alone 1

Additional Baseline Assessment

• Document specific symptoms of hypogonadism (low libido, erectile dysfunction, decreased energy, etc.) 1, 6
• Baseline voiding history or standardized questionnaire (e.g., AUA/IPSS score) 5
• History of sleep apnea 5

Common Pitfalls to Avoid

Do not start testosterone if:

• Only one testosterone measurement obtained (need two separate morning values)
• Hematocrit >50% without further evaluation
• PSA >4.0 ng/ml or abnormal DRE without urology clearance
• Patient lacks documented symptoms consistent with hypogonadism

The single testosterone measurement trap: Many men receive testosterone without proper confirmation testing 7. The Endocrine Society explicitly requires two separate low measurements because testosterone levels fluctuate 1, 2.

The hematocrit oversight: Baseline hematocrit >50% predicts who will develop dangerous erythrocytosis (>54%) on therapy 1. Missing this baseline creates safety risks and monitoring confusion.

Monitoring After Initiation

Once baseline labs confirm candidacy and therapy starts:

• Recheck testosterone, hematocrit, and PSA (if applicable) at 3-6 months 1, 2
• Then annually thereafter
• Stop therapy immediately if hematocrit exceeds 54% 1, 2

The evidence strongly supports this baseline testing algorithm from the 2010 and 2018 Endocrine Society guidelines 1, 2, which represent the most authoritative guidance. The FDA label for testosterone cypionate reinforces the need for baseline hematocrit monitoring and prostate assessment 4.